7 terminated. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Terminated 7 |
| Phase 2 | 2 | Terminated 2 |
Follow Hearing Loss: new trials by email Literature Review of Hearing Loss trials Research Report on Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo - Hearing Loss, Idiopathic Sudden Sensorineural | Phase 3 | Terminated | Auris Medical, Inc. | 56 | 2016-06-01 | 2020-08-07 |
| Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL) D-methionine, Placebo - Noise-induced Hearing Loss | Phase 3 | Terminated | Southern Illinois University | 351 | 2013-09-01 | 2022-06-28 |
| Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial Valganciclovir - Congenital Cytomegalovirus Infection, Sensorineural Hearing Loss | Phase 3 | Terminated | Dr. Ann C.T.M. Vossen | 2 | 2012-06-01 | 2015-06-18 |
| Famvir for Treatment of Hearing in Unilateral Meniere's Disease Famciclovir, Placebo - Meniere's Disease | Phase 3 | Terminated | House Research Institute | 11 | 2011-12-01 | 2021-04-19 |
| Autoimmunity in Inner Ear Disease Corticosteroids, Methotrexate - Hearing Loss, Sensorineural | Phase 3 | Terminated | National Institute on Deafness and Other Communication Disorders (NIDCD) | 1998-03-01 | 2006-04-24 |
Hearing Loss, Sensorineural (3) · Eye Abnormalities (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Retinal Diseases (2) · Retinitis Pigmentosa (2) · Usher Syndromes (2) · Vision Disorders (2) · Autoimmune Diseases (1) · Cytomegalovirus Infections (1) · Deafness (1) · Ear Diseases (1) · Hearing Disorders (1) · Hearing Loss, Noise-Induced (1)
Pathological Conditions, Signs and Symptoms (7) · Ear Diseases (6) · Hearing Disorders (6) · Nervous System Diseases (6) · Neurologic Manifestations (6) · Otorhinolaryngologic Diseases (6) · Sensation Disorders (6) · Signs and Symptoms (6) · Hearing Loss, Sensorineural (3) · Abnormalities, Multiple (2) · Blindness (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Deaf-Blind Disorders (2)
Intravitreal Injections (2) · Adrenal Cortex Hormones (1) · D-JNKI-1 (1) · Famciclovir (1) · Methotrexate (1) · Valganciclovir (1)
Laboratoires Thea (2) · Auris Medical, Inc. (1) · Dr. Ann C.T.M. Vossen (1) · House Research Institute (1) · National Institute on Deafness and Other Communication Disorders (NIDCD) (1) · Southern Illinois University (1)
United States (5) · Netherlands (2) · United Kingdom (2) · Canada (1) · Germany (1) · South Korea (1)
Ann CT Vossen, Dr. (1) · Anne Marie Oudesluys-Murphy, Prof. Dr. (1) · Dr. Jeffrey Harris (1) · Dr. Patrick Brookhouser (1) · Jennifer Derebery, MD (1) · Kathleen Campbell, PhD (1) · Thomas Meier (1)
U01DC003209 (1)